Characteristics of AML patients
| Patient no. . | Age, yr . | FAB . | WBC, × 109/L . | Cytogenetic . | FLT3 . | |
|---|---|---|---|---|---|---|
| ITD . | D835 . | |||||
| 1 | 75 | 5 | 46.5 | 46 XX | 0 | 0 |
| 2 | 51 | 1 | 1.1 | 46 XX | 0 | 0 |
| 3 | 38 | 2 | 1.8 | Tetrasomy 8 | 0 | 0 |
| 4 | 45 | 4 | 216 | 46 XY | 1 | 0 |
| 5 | 67 | t-AML | 7.6 | 46 XY | 0 | 0 |
| 6 | 59 | 4 | 162 | 46 XX | 0 | ND |
| 7 | 43 | 4Eo | 148 | 46 XY, inv (16) | 0 | 0 |
| 8 | 52 | 5 | 142.5 | 46 XY, t(3;6) | 1 | 0 |
| 9 | 53 | 1 | 225 | 46 XX | 0 | ND |
| 10 | 43 | 2 | 28 | 46 XY, t(8;21) | 0 | 0 |
| 11 | 53 | 4 | 54.5 | 46XX | 1 | 0 |
| 12 | 59 | 1 | 125 | Penta8; +(10); +(13) | 1 | ND |
| 13 | 46 | 1 | 33.3 | 46 XX | 1 | 0 |
| 14 | 52 | 1 | 167 | 46 XX | 1 | 0 |
| 15 | 53 | 4Eo | 98.6 | 46 XX, inv(16) | 0 | 0 |
| 16 | 40 | 5 | 107.7 | 46 XY | 1 | 0 |
| 17 | 64 | 4 | 91 | 46 XY, t(2;21) | 0 | ND |
| 18 | 60 | 2 | 70 | 46 XX | 0 | 0 |
| 19 | 59 | 4 | 20 | 46 XX | 0 | 0 |
| 20 | 72 | 2 | 18.9 | Complex | 0 | ND |
| 21 | 41 | 4Eo | 57.8 | 46 XY, t(4;16) | 0 | 0 |
| 22 | 54 | 2 | 35.7 | 47 XX, +(8) | 0 | ND |
| 23 | 35 | 2 | 3.3 | 46 XY, t(8;21) | 0 | 0 |
| 24 | 41 | 2 | 21 | 46 XY, t(8;21) | 0 | 0 |
| 25 | 56 | 4Eo | 23 | 46 XX, inv (16) | 0 | 0 |
| 26 | 15 | 2 | 11.2 | 46 XY, t(8;21) | 0 | ND |
| 27 | 54 | 2 | 11 | 46 XY, t(8;21) | 0 | 0 |
| 28 | 27 | 3 | 18.9 | 46 XX, t(15;17) | 1 | ND |
| 29 | 73 | 3 | 1.3 | 46 XY, t(15;17) | 0 | ND |
| 30 | 29 | 2 | 33.5 | 46 XX, t(8;21) | 0 | 0 |
| 31 | 44 | 2 | 211.8 | 46 XY, t(8;21) | 0 | 0 |
| 32 | 63 | 3 | 13.3 | 46 XX, t(15;17) | 0 | 1 |
| 33 | 45 | 3 | 10 | 46 XY, t(15;17) | 1 | ND |
| 34 | 42 | 3 | 42.1 | 46 XY,t(15;17) | 1 | 0 |
| 35 | 45 | t-AML | 39.6 | 45 XX, inv(3), del(5) | 0 | 0 |
| 36 | 78 | 2 | 98.6 | 46 XX, inv(3) | 1 | 0 |
| 37 | 62 | 2 | 142.5 | 46 XX, t(3;6), 7q− | 1 | 0 |
| 38 | 49 | 2 | 3.1 | Complex | 1 | ND |
| 39 | 66 | 2 | 106 | Complex | 0 | ND |
| 40 | 48 | 2 | 4.4 | Complex | ND | ND |
| 41 | 74 | 1 | 88 | 46 XY, t(8;22),5q−,20q− | ND | ND |
| 42 | 81 | 2 | 50 | 46 XY | 0 | 1 |
| 43 | 79 | t-AML | 188 | 47 XY, +(8) | 0 | 0 |
| 44 | 61 | 2 | 39.5 | 46 XY | 1 | 0 |
| 45 | 80 | 2 | 38.5 | 47 XY, +(8) | 0 | ND |
| 46 | 77 | 1 | 195 | 46 XX | 0 | 0 |
| 47 | 70 | 1 | 14 | Complex | 0 | ND |
| 48 | 63 | t-AML | 41 | Complex | 0 | 0 |
| 49 | 33 | 2 | 60.4 | 46 X−Y+X, t(8;21) | 1 | 0 |
| 50 | 76 | 4 | 136 | 47 XX, +(11) | 0 | 1 |
| 51 | 73 | 2 | 13.3 | 46 XX | 0 | ND |
| 52 | 68 | t-AML | 82.7 | 45 XY, −(7) | 0 | ND |
| 53 | 79 | 2 | 1.4 | Complex | 0 | 0 |
| 54 | 69 | 2 | 10.6 | 46 XY | ND | ND |
| 55 | 70 | t-AML | 19 | 46 XY, (7)q− | 0 | ND |
| 56 | 56 | 1 | 26.9 | ND | 1 | ND |
| 57 | 53 | 1 | 27.9 | 46 XY | 0 | 0 |
| 58 | 19 | 5 | 15.2 | 5q−, 17+, −20, t(5;17) | 0 | ND |
| 59 | 66 | 2 | 5,8 | Complex | 0 | ND |
| 60 | 60 | 2 | 41 | 46 XY | 0 | ND |
| 61 | 76 | 1 | 6.5 | 46 XX | ND | ND |
| 62 | 68 | 2 | 1.2 | Complex; 5q−;17p− | 0 | ND |
| Patient no. . | Age, yr . | FAB . | WBC, × 109/L . | Cytogenetic . | FLT3 . | |
|---|---|---|---|---|---|---|
| ITD . | D835 . | |||||
| 1 | 75 | 5 | 46.5 | 46 XX | 0 | 0 |
| 2 | 51 | 1 | 1.1 | 46 XX | 0 | 0 |
| 3 | 38 | 2 | 1.8 | Tetrasomy 8 | 0 | 0 |
| 4 | 45 | 4 | 216 | 46 XY | 1 | 0 |
| 5 | 67 | t-AML | 7.6 | 46 XY | 0 | 0 |
| 6 | 59 | 4 | 162 | 46 XX | 0 | ND |
| 7 | 43 | 4Eo | 148 | 46 XY, inv (16) | 0 | 0 |
| 8 | 52 | 5 | 142.5 | 46 XY, t(3;6) | 1 | 0 |
| 9 | 53 | 1 | 225 | 46 XX | 0 | ND |
| 10 | 43 | 2 | 28 | 46 XY, t(8;21) | 0 | 0 |
| 11 | 53 | 4 | 54.5 | 46XX | 1 | 0 |
| 12 | 59 | 1 | 125 | Penta8; +(10); +(13) | 1 | ND |
| 13 | 46 | 1 | 33.3 | 46 XX | 1 | 0 |
| 14 | 52 | 1 | 167 | 46 XX | 1 | 0 |
| 15 | 53 | 4Eo | 98.6 | 46 XX, inv(16) | 0 | 0 |
| 16 | 40 | 5 | 107.7 | 46 XY | 1 | 0 |
| 17 | 64 | 4 | 91 | 46 XY, t(2;21) | 0 | ND |
| 18 | 60 | 2 | 70 | 46 XX | 0 | 0 |
| 19 | 59 | 4 | 20 | 46 XX | 0 | 0 |
| 20 | 72 | 2 | 18.9 | Complex | 0 | ND |
| 21 | 41 | 4Eo | 57.8 | 46 XY, t(4;16) | 0 | 0 |
| 22 | 54 | 2 | 35.7 | 47 XX, +(8) | 0 | ND |
| 23 | 35 | 2 | 3.3 | 46 XY, t(8;21) | 0 | 0 |
| 24 | 41 | 2 | 21 | 46 XY, t(8;21) | 0 | 0 |
| 25 | 56 | 4Eo | 23 | 46 XX, inv (16) | 0 | 0 |
| 26 | 15 | 2 | 11.2 | 46 XY, t(8;21) | 0 | ND |
| 27 | 54 | 2 | 11 | 46 XY, t(8;21) | 0 | 0 |
| 28 | 27 | 3 | 18.9 | 46 XX, t(15;17) | 1 | ND |
| 29 | 73 | 3 | 1.3 | 46 XY, t(15;17) | 0 | ND |
| 30 | 29 | 2 | 33.5 | 46 XX, t(8;21) | 0 | 0 |
| 31 | 44 | 2 | 211.8 | 46 XY, t(8;21) | 0 | 0 |
| 32 | 63 | 3 | 13.3 | 46 XX, t(15;17) | 0 | 1 |
| 33 | 45 | 3 | 10 | 46 XY, t(15;17) | 1 | ND |
| 34 | 42 | 3 | 42.1 | 46 XY,t(15;17) | 1 | 0 |
| 35 | 45 | t-AML | 39.6 | 45 XX, inv(3), del(5) | 0 | 0 |
| 36 | 78 | 2 | 98.6 | 46 XX, inv(3) | 1 | 0 |
| 37 | 62 | 2 | 142.5 | 46 XX, t(3;6), 7q− | 1 | 0 |
| 38 | 49 | 2 | 3.1 | Complex | 1 | ND |
| 39 | 66 | 2 | 106 | Complex | 0 | ND |
| 40 | 48 | 2 | 4.4 | Complex | ND | ND |
| 41 | 74 | 1 | 88 | 46 XY, t(8;22),5q−,20q− | ND | ND |
| 42 | 81 | 2 | 50 | 46 XY | 0 | 1 |
| 43 | 79 | t-AML | 188 | 47 XY, +(8) | 0 | 0 |
| 44 | 61 | 2 | 39.5 | 46 XY | 1 | 0 |
| 45 | 80 | 2 | 38.5 | 47 XY, +(8) | 0 | ND |
| 46 | 77 | 1 | 195 | 46 XX | 0 | 0 |
| 47 | 70 | 1 | 14 | Complex | 0 | ND |
| 48 | 63 | t-AML | 41 | Complex | 0 | 0 |
| 49 | 33 | 2 | 60.4 | 46 X−Y+X, t(8;21) | 1 | 0 |
| 50 | 76 | 4 | 136 | 47 XX, +(11) | 0 | 1 |
| 51 | 73 | 2 | 13.3 | 46 XX | 0 | ND |
| 52 | 68 | t-AML | 82.7 | 45 XY, −(7) | 0 | ND |
| 53 | 79 | 2 | 1.4 | Complex | 0 | 0 |
| 54 | 69 | 2 | 10.6 | 46 XY | ND | ND |
| 55 | 70 | t-AML | 19 | 46 XY, (7)q− | 0 | ND |
| 56 | 56 | 1 | 26.9 | ND | 1 | ND |
| 57 | 53 | 1 | 27.9 | 46 XY | 0 | 0 |
| 58 | 19 | 5 | 15.2 | 5q−, 17+, −20, t(5;17) | 0 | ND |
| 59 | 66 | 2 | 5,8 | Complex | 0 | ND |
| 60 | 60 | 2 | 41 | 46 XY | 0 | ND |
| 61 | 76 | 1 | 6.5 | 46 XX | ND | ND |
| 62 | 68 | 2 | 1.2 | Complex; 5q−;17p− | 0 | ND |
FAB indicates French-American-British classification; WBC, white blood cell count; FLT3-ITD, FLT3-internal tandem duplication; FLT3-D835, FLT3 mutation in the activation loop; t-AML, transformed-AML; and ND, not done.